Aktie A3D39C HTG MOLECULAR DIAGNOSTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen HTG Molecular Diagnostics, Inc.

Aktien

A3D39C

US40434H3021

HTGMQ

Markt geschlossen - OTC Markets
Andere Börsenplätze
 15:31:07 26.06.2024 		% 5 Tage % 1. Jan.
0.0015 USD 0.00% Intraday Chart für HTG Molecular Diagnostics, Inc. -40.00% +15.38%
2023 Treuhänder/Prüfer nach Chapter 11 für HTG Molecular Diagnostics, Inc. ernannt CI
2023 Htg Molecular Diagnostics, Inc. gibt die Beendigung des Beschäftigungsverhältnisses von Byron T. Lawson als Senior Vice President und Chief Commercial Officer bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.
Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.
Trustee/Examiner Appointed Under Chapter 11 for HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index
HTG MOLECULAR DIAGNOSTICS, INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index
Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer
HTG Molecular Diagnostics, Inc. Filed for Bankruptcy
HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention
HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization
Top Premarket Gainers
HTG Highlights the Advantages of Its Drug Discovery Engine
HTG Molecular Diagnostics : Reports First Quarter 2023 Results and Provides Recent Business Highlights - Form 8-K
HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights
HTG MOLECULAR DIAGNOSTICS, INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
HTG MOLECULAR DIAGNOSTICS, INC : Other Events (form 8-K)
HTG Provides Update on Drug Discovery Partnering Initiative
HTG Announces Key First Quarter Milestone Achievements for Drug Discovery
HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D39C Aktie
  4. Nachrichten HTG Molecular Diagnostics, Inc.
  5. Andere Sprachen